西地尼布联合顺铂培美曲塞治疗初治不可切恶性胸膜间皮瘤的II期试验
PURPOSE: Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM).…
要点
- 3-4级腹泻、脱水、高血压、体重下降增加,毒性限制进一步开发
核心结论
- 西地尼布联合铂类-培美曲塞改善不可切MPM的RECIST v1.1 PFS和改良RECIST缓解率。
- 总生存无显著差异,且毒性特征不支持在MPM中进一步开发西地尼布。
研究设计与样本
- SWOG S0905为随机II期试验,比较西地尼布或安慰剂联合铂类-培美曲塞6周期后维持治疗。
- 主要终点为RECIST v1.1 PFS,设计在单侧0.1水平检测差异。
主要发现
- 总生存无显著差异。
- 西地尼布组3-4级腹泻、脱水、高血压和体重下降更多。
临床怎么用
- 西地尼布联合铂类-培美曲塞可改善PFS和缓解率,但总生存无获益且毒性增加。
- 因毒性特征和微小生存获益,不推荐在MPM中进一步开发该联合方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, demonstrated therapeutic potential in a prior phase I trial. We evaluated a phase II trial for efficacy. PATIENTS AND METHODS: SWOG S0905 (ClinicalTrials.gov identifier: NCT01064648) randomly assigned cediranib or placebo with platinum-pemetrexed for six cycles followed by maintenance cediranib or placebo in unresectable chemotherapy-naïve patients with MPM of any histologic subtype. Primary end point was Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 progression-free survival (PFS). Secondary end points included overall survival, PFS by modified RECIST v1.1, response (modified RECIST and RECIST v1.1), disease control, and safety/toxicity. The trial was designed to detect a difference in RECIST v1.1 PFS at the one-sided 0.1 level using a stratified log-rank test. RESULTS: Ninety-two eligible patients were enrolled (75% epithelioid and 25% biphasic or sarcomatoid). The cediranib arm had more grade 3 and 4 diarrhea, dehydration, hypertension, and weight loss. Cediranib improved PFS by RECIST v1.1 (hazard ratio, 0.71; 80% CI, 0.54 to 0.95; P = .062; 7.2 months v 5.6 months) and increased modified RECIST v1.1 response (50% v 20%; P = .006). By modified RECIST v1.1, cediranib numerically increased PFS (hazard ratio, 0.77; 80% CI, 0.59 to 1.02; P = .12; median, 6.9 months v 5.6 months). No significant difference in overall survival was observed. CONCLUSION: The addition of cediranib to platinum-pemetrexed improved PFS by RECIST v1.1 and response rate by modified RECIST in patients with unresectable MPM. Whereas adding antiangiogenics to chemotherapy has been a successful strategy for some patients, the cediranib toxicity profile and small incremental survival benefit precludes additional development in MPM.
引用
- Tsao AS, Miao J, Wistuba II, et al. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019. PMID: 31386610. doi:10.1200/JCO.19.00269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。